Synonym
Trandolapril, Mavik, Gopten, Odrik, RU 44570
IUPAC/Chemical Name
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
InChi Key
VXFJYXUZANRPDJ-WTNASJBWSA-N
InChi Code
InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
SMILES Code
O=C([C@H]1N(C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)[C@@]3([H])CCCC[C@]3([H])C1)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
DMF: 15 mg/ml; DMSO: 25 mg/ml; Ethanol: 0.25 mg/ml; PBS (pH 7.2): 1 mg/ml.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
430.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cohen V, Jellinek SP, Fancher L, Sangwan G, Wakslak M, Marquart E, Farahani C. Tarka® (trandolapril/verapamil hydrochloride extended-release) overdose. J Emerg Med. 2011 Mar;40(3):291-5. doi: 10.1016/j.jemermed.2008.10.015. Epub 2009 Feb 26. Review. PubMed PMID: 19249183.
2: Diaz A, Ducharme A. Update on the use of trandolapril in the management of cardiovascular disorders. Vasc Health Risk Manag. 2008;4(6):1147-58. Review. PubMed PMID: 19337528; PubMed Central PMCID: PMC2663436.
3: Sharma SK, Ruggenenti P, Remuzzi G. Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. Vasc Health Risk Manag. 2007;3(4):453-65. Review. PubMed PMID: 17969376; PubMed Central PMCID: PMC2291330.
4: Muijsers RB, Curran MP, Perry CM. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Drugs. 2002;62(17):2539-67. Review. PubMed PMID: 12421112.
5: Widimský J. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother. 2000 Mar;1(3):515-35. Review. PubMed PMID: 11249535.
6: Buksa M. [Trandolapril in the prevention of the sequelae of left ventricular systolic dysfunction after acute myocardial infarct]. Med Arh. 2000;54(2):103-6. Review. Croatian. PubMed PMID: 10934839.
7: Ottesen MM, Jørgensen S, Kjøller E, Videbaek J, Køber L, Torp-Pedersen C. Age-distribution, risk factors and mortality in smokers and non-smokers with acute myocardial infarction: a review. TRACE study group. Danish Trandolapril Cardiac Evaluation. J Cardiovasc Risk. 1999 Oct;6(5):307-9. Review. PubMed PMID: 10534133.
8: Hansen JF, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Pedersen-Bjergaard O. Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). J Hypertens Suppl. 1997 Mar;15(2):S119-22. Review. PubMed PMID: 9218208.
9: Miyazaki M, Kawamoto T, Okunishi H. Vascular affinity of trandolapril. Am J Hypertens. 1995 Oct;8(10 Pt 2):63S-67S. Review. PubMed PMID: 8845086.
10: Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994 Jul;48(1):71-90. Review. PubMed PMID: 7525196.
11: Gaillard CA, de Leeuw PW. Clinical experiences with trandolapril. Am Heart J. 1993 May;125(5 Pt 2):1542-6. Review. PubMed PMID: 8480627.
12: García Donaire JA, Ruilope LM. Trandolapril/verapamil combination in hypertensive diabetic patients. Vasc Health Risk Manag. 2007;3(1):77-82. Review. PubMed PMID: 17583177; PubMed Central PMCID: PMC1994049.
13: Reynolds NA, Wagstaff AJ, Keam SJ. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs. 2005;65(13):1893-914. Review. PubMed PMID: 16114984.
14: Guay DR. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003 Mar;25(3):713-75. Review. PubMed PMID: 12852701.
15: Coca A, Rabasseda X. Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study. Drugs Today (Barc). 2003 Jan;39(1):5-18. Review. PubMed PMID: 12669106.
16: Peters DC, Noble S, Plosker GL. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 1998 Nov;56(5):871-93. Review. PubMed PMID: 9829159.
17: Dooley M, Goa KL. Fixed combination verapamil SR/trandolapril. Drugs. 1998 Nov;56(5):837-44; discussion 845-6. Review. PubMed PMID: 9829157.
18: Hansen JF. Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. J Hypertens Suppl. 1998 Jan;16(1):S71-4. Review. PubMed PMID: 9534101.
19: Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl. 1997 Mar;15(2):S51-3. Review. PubMed PMID: 9218199.
20: Kirchengast M. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. J Hypertens Suppl. 1997 Mar;15(2):S27-33. Review. PubMed PMID: 9218195.
